Table 1.
Baseline characters and complications during treatment of the two study groups
| Value | Group | |||||
|---|---|---|---|---|---|---|
| PovI group (n=41) | Control group (n=35) | |||||
| Mean | Minimum | Maximum | Mean | Minimum | Maximum | |
| Age (years) | 32.12±15.3 | 5.0 | 76.0 | 32.34±17.7 | 2.0 | 62.0 |
| Sex (male: female) | 26:15 | 18:17 | ||||
| PCR (positive: negative) | 71:29 | Not sent | ||||
| Time since onset (days) | 4.4±2.5 | 2.0 | 12.0 | 4.9±3.1 | 2.0 | 14.0 |
| Eye involved (BE:RE:LE)* | 29:4:8 | 23:7:5 | ||||
| Stiffness/puffiness | 1.5±0.6 | 1.0 | 3.0 | 1.7±0.6 | 1.0 | 3.0 |
| Discomfort | 1.5±0.7 | 0.0 | 3.0 | 1.9±0.6 | 1.0 | 3.0 |
| Congestion | 2.3±0.6 | 1.0 | 3.0 | 2.2±0.8 | 0.0 | 3.0 |
| Follicles | 2.2±0.6 | 1.0 | 3.0 | 1.9±0.8 | 0.0 | 3.0 |
| Composite factor | 1.87±0.5 | 1.3 | 2.8 | 1.94±0.5 | 0.8 | 3.0 |
| Epitheliopathy incidence (%)† | 51 | 71 | ||||
| PovI irritation score | 0.57±0.56 | 0 | 2 | Not applicable | ||
| SEI incidence (%)† | 9.8 | 57.1 | ||||
| Membrane incidence (%)† | 34.1 | 37.1 | ||||
| SEI at one month (%) | 0.0 | 31 | ||||
| Subconjunctival scarring (%) | 7 | 43 | ||||
*BE=Both eyes, RE=Right eye, LE=Left eye,†Fresh incidence after starting treatment, PovI=Povidone Iodine, PCR=Polymerase chain reaction, SEI= subepithelial infiltrates